UPDATE: Jefferies Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $492 As Firm Attributes Optimism Towards 'recent adverse events that have arisen with Novartis' Beovu, which will likely dampen its uptake and minimizes competitive risk.'
Benzinga Newsdesk